Xenetic Biosciences, Inc. Aktie News

Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies Ended the quarter with $4.8 million of cash to fund operations FRAMINGHAM, MA / ACCESS Newswire / August 13, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical com...

Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its ...

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date FRAMINGHAM, MA / ACCESS Newswire / July 23, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncolog...

Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNess Company evaluating systemic recombinant human DNase I (DNase I) in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors FRAMINGHAM, MA / ACCES...

Strategic focus on exploratory investigator-initiated clinical studies with institutional partners Continued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic carcinoma Ended the quarter with $5.2 million of cash to fund operations    FRAMINGHAM, MA / ACCESS Newswire / May 14, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the...

- Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting - Watch the "What This Means" video here FRAMINGHAM, MA / ACCESS Newswire / April 9, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or th...